Valeant

Stocktake: betting the farm is always dumb – whether you make a bundle or lose the lot

Trade union and contact lens group to focus on talks aiming to resolve pay dispute

Company counters Siptu plan for work stoppages and overtime ban with warning that jobs will be cuts

Recently acquired Par Pharmaceuticals drives revenue but Endo still reports €200m loss

US pharma group accused of price gouging over huge increase in price of Aloquin

Dublin-based Botox maker unveils €573m agreement to buy Vitae Pharmaceuticals

In Dublin Smurfit Kappa is buoyed by better-than-expected trading update

What Papa brings to the party is a depth of experience from over 30 years in the business

A look around the world’s stock markets

The prime focus of Valeant was on maximising profit on often older drugs

Aryzta and Valeant chief executives in limelight for differing yet similar reasons

Endo International, another Irish-headquartered specialty drugmaker, fell 23 per cent

Farewell to the Brics, morality and the hedge fund manager and exploiting inattention

Investors can be led astray by firms using non-generally accepted accounting principles

Eye-popping growth and questionable acquisitions raise far too many questions

‘Price-gouging like this . . . is outrageous’ she wrote as drug price rose from $13.50 to $750

Allergan employs about 900 here, most at its manufacturing plant in Westport

Actavis must be getting dizzy from all the approaches

Botox maker’s resistance an unexpected twist for Valeant

Quebec-based pharmaceutical company takes its hostile $50.8 billion bid directly to shareholders

Contact lens maker wants 20 per cent pay cut on top of 200 redundancies

Waterford workers appear to have little leverage in battle to soften swingeing cuts